thalidomide has been researched along with Leprosy, Cutaneous in 104 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind, double-dummy controlled study, 22 men with erythema nodosum leprosum (ENL) received six capsules containing either 100 mg (group A, n = 12) or 300 mg (group B, n = 10) of thalidomide daily for one week." | 9.11 | A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. ( Abalos, RM; Balagon, MV; Cellona, RV; Fajardo, TT; Kook, KA; Palmer, JP; Tan, EV; Thomas, SD; Villahermosa, LG; Walsh, DS; Walsh, GP; Wittes, J, 2005) |
| "Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy." | 8.87 | [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum]. ( Gidoh, M; Goto, M; Hatano, K; Ishida, Y; Ishii, N; Kumano, K; Nogami, R; Okano, Y; Ozaki, M; Yamada, A; Yotsu, RR, 2011) |
| "Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum." | 8.12 | Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report. ( Bahamondes, L; Baracat, EC; de Almeida, PG; Duarte, DC; Ferreira-Filho, ES; Guimarães, ALM; Soares-Júnior, JM; Sorpreso, ICE, 2022) |
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 7.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is well known as a steroid sparing drug in Erythema Nodosum leprosum (ENL) reaction in leprosy." | 7.83 | Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study. ( Charles, DE; Darlong, J; Govindharaj, P; Mani, S; Menzies, A, 2016) |
| "Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL)." | 7.75 | Thalidomide levels in patients with erythema nodosum leprosum. ( Valente, Mdo S; Vieira, JL, 2009) |
| "Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men." | 7.74 | A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008) |
| "The immunomodulatory drug thalidomide is the treatment of choice for erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of multibacillary leprosy." | 7.73 | Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. ( Albert, M; Butlin, CR; Haslett, PA; Hawksworth, R; Kaplan, G; Lemaster, J; Lubinsky, AS; Macdonald, M; Manandhar, R; Roche, P; Shah, M; Shrestha, N; Worley, J, 2005) |
| "Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL)." | 7.68 | Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. ( Berhan, TY; Ejigu, M; Haile-Mariam, HS; Shannon, EJ; Tasesse, G, 1992) |
| "Immunologic and clinical manifestations of erythema nodosum leprosum (ENL) and their response to thalidomide therapy were evaluated." | 7.68 | The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. ( Kaplan, G; Miguel, CP; Miranda, A; Nery, JA; Sampaio, EP; Sarno, EN; Viana, SM, 1993) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 6.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "reported that the bone marrow of multiple myeloma (MM) patients was rich in blood vessels and that there is a causal relationship between the activity of MM and marrow angiogenesis." | 6.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae." | 6.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 5.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Thalidomide has proven to be a steroid-sparing agent and is useful in controlling the reactions." | 5.56 | Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. ( Pallapati, MS; Srikantam, A; Tarwater, P; Upputuri, B, 2020) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 5.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| "Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum." | 5.39 | Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. ( Burgués-Calderón, M; de la Hera, I; Fuertes, L; Hebe Petiti-Martin, G; Rivera-Díaz, R; Vanaclocha, F; Villar-Buill, M, 2013) |
| "In a randomized, double-blind, double-dummy controlled study, 22 men with erythema nodosum leprosum (ENL) received six capsules containing either 100 mg (group A, n = 12) or 300 mg (group B, n = 10) of thalidomide daily for one week." | 5.11 | A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. ( Abalos, RM; Balagon, MV; Cellona, RV; Fajardo, TT; Kook, KA; Palmer, JP; Tan, EV; Thomas, SD; Villahermosa, LG; Walsh, DS; Walsh, GP; Wittes, J, 2005) |
| "A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment." | 5.08 | IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. ( Estrada-Garcia, I; Estrada-Parra, S; Favila-Castillo, L; Gomez-Melgar, M; Partida-Sanchez, S; Pedraza-Sanchez, S; Saul, A, 1998) |
| "We report a patient with severe multi-bacillary leprosy complicated by recurrent episodes of erythema nodosum necrotisans that required thalidomide and/or corticosteroids during follow-up." | 4.87 | A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature. ( Belfort, EC; Benard, G; Carvalho, NB; Gakiya, E; Pagliari, C; Sakai-Valente, NY; Shikanai-Yasuda, MA; Trindade, MÂ, 2011) |
| "Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy." | 4.87 | [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum]. ( Gidoh, M; Goto, M; Hatano, K; Ishida, Y; Ishii, N; Kumano, K; Nogami, R; Okano, Y; Ozaki, M; Yamada, A; Yotsu, RR, 2011) |
| " We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature." | 4.85 | Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. ( Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN, 2009) |
| "Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum." | 4.12 | Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report. ( Bahamondes, L; Baracat, EC; de Almeida, PG; Duarte, DC; Ferreira-Filho, ES; Guimarães, ALM; Soares-Júnior, JM; Sorpreso, ICE, 2022) |
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 3.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is well known as a steroid sparing drug in Erythema Nodosum leprosum (ENL) reaction in leprosy." | 3.83 | Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study. ( Charles, DE; Darlong, J; Govindharaj, P; Mani, S; Menzies, A, 2016) |
| "In the present study, we set out to explore the T helper 17 (TH17) lymphocyte subset, the hallmark of T-cell plasticity, in skin biopsies from patients with erythema nodosum leprosum (ENL) who were treated with thalidomide." | 3.78 | Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. ( Giovinazzo, J; Haslett, P; Kaplan, G; Levis, WR; Martiniuk, F; Shahidullah, R; Tan, AU, 2012) |
| "Erythema nodosum leprosum (ENL) is an inflammatory reaction that may occur in multibacillary leprosy patients, and thalidomide is the treatment of choice." | 3.77 | In vitro thalidomide does not interfere with the activation of complement by M. leprae. ( Morales, MJ; Sandoval, FG; Shannon, EJ, 2011) |
| "Thalidomide is used for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL)." | 3.75 | Thalidomide levels in patients with erythema nodosum leprosum. ( Valente, Mdo S; Vieira, JL, 2009) |
| "Thalidomide is the drug of choice in the treatment of severe erythema nodosum leprosum (ENL) in men." | 3.74 | A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide. ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008) |
| "The immunomodulatory drug thalidomide is the treatment of choice for erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of multibacillary leprosy." | 3.73 | Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. ( Albert, M; Butlin, CR; Haslett, PA; Hawksworth, R; Kaplan, G; Lemaster, J; Lubinsky, AS; Macdonald, M; Manandhar, R; Roche, P; Shah, M; Shrestha, N; Worley, J, 2005) |
| "Changes in peripheral blood platelet counts associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing, in each patient, the value obtained on the day thalidomide therapy commenced with the average of the three preceding values." | 3.71 | Elevated platelet counts and thrombocytosis in erythema nodosum leprosum. ( Rea, TH, 2002) |
| "Changes in hemoglobin (HGB) and serum albumin (SA) concentration associated with the onset of symptomatic erythema nodosum leprosum (ENL) were studied by comparing the values obtained on the day thalidomide or prednisone therapy commenced, with each patients' preceding values." | 3.71 | Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. ( Rea, TH, 2001) |
| "Immunologic and clinical manifestations of erythema nodosum leprosum (ENL) and their response to thalidomide therapy were evaluated." | 3.68 | The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. ( Kaplan, G; Miguel, CP; Miranda, A; Nery, JA; Sampaio, EP; Sarno, EN; Viana, SM, 1993) |
| "Thalidomide is well documented as being an effective drug in the treatment of erythema nodosum leprosum (ENL)." | 3.68 | Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. ( Berhan, TY; Ejigu, M; Haile-Mariam, HS; Shannon, EJ; Tasesse, G, 1992) |
| "This analysis allows us to think beyond the safe use of thalidomide, but the safety provided by any type of monitoring system." | 2.82 | Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety? ( de Jesus, SM; Leite, SN; Santana, RS, 2022) |
| "Thalidomide has been shown to be a highly effective drug for the treatment of ENL." | 2.73 | Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. ( de Matos, HJ; Duppre, NC; Nery, JA; Sales, AM; Sampaio, EP; Sarno, EN, 2007) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 2.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "Thalidomide has a rapid action but its use is limited due the teratogenicity and neurotoxicity." | 2.58 | Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. ( Costa, PDSS; Daxbacher, ELR; Fraga, LR; Kowalski, TW; Schuler-Faccini, L; Vianna, FSL, 2018) |
| "Treatment with thalidomide showed a significant remission of skin lesions compared to acetylsalicylic acid (aspirin) (RR 2." | 2.45 | Interventions for erythema nodosum leprosum. ( Lockwood, DN; Ramirez, J; Richardus, JH; van Brakel, WH; Van Veen, NH, 2009) |
| "Treatment with thalidomide showed a significant benefit compared to aspirin (RR 2." | 2.45 | Interventions for erythema nodosum leprosum. A Cochrane review. ( Lockwood, DN; Ramirez, J; Richardus, JH; Van Brakel, WH; Van Veen, NH, 2009) |
| "Leprosy is not eliminated." | 2.43 | Treatment of leprosy: science or politics? ( Naafs, B, 2006) |
| "reported that the bone marrow of multiple myeloma (MM) patients was rich in blood vessels and that there is a causal relationship between the activity of MM and marrow angiogenesis." | 2.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide is being investigated for treatment of renal cell carcinoma, and liver and thyroid cancers." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "Thalidomide was withdrawn from the market in the early sixties because of its teratogenic effects." | 2.41 | [Thalidomide: new uses for an old drug]. ( Sonneveld, P; Wu, KL, 2002) |
| "Leprosy is a chronic infection of the skin and nerves caused by Mycobacterium leprae." | 2.41 | Thalidomide in the treatment of leprosy. ( Kook, KA; Resztak, KE; Scheffler, MA; Stirling, DI; Teo, S; Thomas, SD; Zeldis, JB, 2002) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 1.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 1.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| "Thalidomide has proven to be a steroid-sparing agent and is useful in controlling the reactions." | 1.56 | Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. ( Pallapati, MS; Srikantam, A; Tarwater, P; Upputuri, B, 2020) |
| "Here, we present a case of ulnar neuritis presenting in a patient with lepromatous leprosy four years after treatment of initial infection, with subsequent improvement after corticosteroid burst while maintained on thalidomide therapy." | 1.51 | Late-onset ulnar neuritis following treatment of lepromatous leprosy infection. ( Schofield, C; Wellington, T, 2019) |
| "Thalidomide treatment reduced PTX3 in the serum 7 days after starting treatment." | 1.46 | Elevated Pentraxin-3 Concentrations in Patients With Leprosy: Potential Biomarker of Erythema Nodosum Leprosum. ( Amadeu, TP; da Silva, CO; de Carvalho, DS; Ferreira, H; Hacker, MA; Mendes, MA; Nery, JAC; Pinheiro, RO; Prata, RBDS; Sampaio, EP; Sarno, EN; Schmitz, V; Silva, BJA, 2017) |
| "Thalidomide treatment is extremely effective at ameliorating ENL symptoms." | 1.43 | Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. ( Amadeu, TP; Barbosa, MG; Brandão, SS; Costa, Fda M; Dos Santos, JB; Ferreira, H; Hacker, Mde A; Machado, Ade M; Mendes, MA; Nery, JA; Pacheco, Fdos S; Pinheiro, RO; Prata, RB; Rodrigues, LS; Sales, AM; Sarno, EN; Schmitz, V, 2016) |
| "Type 2 lepra reaction is a Th2-mediated type III hypersensitivity reaction in leprosy, with a characteristic cutaneous manifestation in the form of erythema nodosum leprosum (ENL)." | 1.40 | Rare atypical presentations in Type 2 lepra reaction: a case series. ( Badad, A; Mitra, D; Neema, S; Vasudevan, B; Verma, R; Vijendran, P, 2014) |
| "Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum." | 1.39 | Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. ( Burgués-Calderón, M; de la Hera, I; Fuertes, L; Hebe Petiti-Martin, G; Rivera-Díaz, R; Vanaclocha, F; Villar-Buill, M, 2013) |
| "Leprosy and vitiligo are common affections in the West Indies." | 1.31 | High prevalence of vitiligo in lepromatous leprosy. ( Boisseau-Garsaud, AM; Garsaud, P; Helenon, R; Quist, D; Saint-Cyr, I; Vezon, G, 2000) |
| "Treatment with thalidomide led to rapid regression." | 1.30 | [Bullous erythema nodosum leprosum. A case report in French Guiana]. ( About, V; Couppié, P; Heid, E; Pradinaud, R; Sainte-Marie, D, 1998) |
| "Thalidomide therapy was required to treat the systemic manifestations of ENL." | 1.28 | Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. ( Kaplan, G; Malta, AM; Moreira, AL; Sampaio, EP; Sarno, EN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.92) | 18.7374 |
| 1990's | 28 (26.92) | 18.2507 |
| 2000's | 38 (36.54) | 29.6817 |
| 2010's | 23 (22.12) | 24.3611 |
| 2020's | 13 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira-Filho, ES | 1 |
| Bahamondes, L | 1 |
| Duarte, DC | 1 |
| Guimarães, ALM | 1 |
| de Almeida, PG | 1 |
| Soares-Júnior, JM | 1 |
| Baracat, EC | 1 |
| Sorpreso, ICE | 1 |
| Savitha, B | 1 |
| Sardana, K | 2 |
| Kumari, R | 1 |
| Khurana, A | 2 |
| Sinha, S | 1 |
| Sachdeva, S | 1 |
| Abril-Pérez, C | 1 |
| Palacios-Diaz, RD | 1 |
| Navarro-Mira, MÁ | 1 |
| Botella-Estrada, R | 1 |
| Bathula, S | 1 |
| Mathachan, SR | 1 |
| Ahuja, A | 1 |
| Paliwal, P | 1 |
| Costa, PDSS | 4 |
| Maciel-Fiuza, MF | 3 |
| Kowalski, TW | 4 |
| Fraga, LR | 4 |
| Feira, MF | 3 |
| Camargo, LMA | 3 |
| Caldoncelli, DIO | 3 |
| Silveira, MIDS | 3 |
| Schuler-Faccini, L | 4 |
| Vianna, FSL | 4 |
| Wellington, T | 1 |
| Schofield, C | 1 |
| Pacheco, FS | 1 |
| Prata, RBDS | 2 |
| Brandão, SS | 2 |
| Ferreira, H | 3 |
| Rodrigues, TF | 1 |
| Brandão Dos Santos, J | 1 |
| da Silva, CO | 2 |
| Tavares, IF | 1 |
| Mendes, MA | 3 |
| Rodrigues, ACDP | 1 |
| Machado, AM | 1 |
| Nery, JADC | 1 |
| Amadeu, TP | 3 |
| Moraes, MO | 1 |
| Sarno, EN | 8 |
| Schmitz, V | 3 |
| Jesus, SM | 1 |
| Santana, RS | 2 |
| Leite, SN | 2 |
| Thangaraju, P | 1 |
| Venkatesan, S | 1 |
| Gurunthalingam, M | 1 |
| Babu, S | 1 |
| T, T | 1 |
| Sánchez-Martínez, EM | 1 |
| Melgosa-Ramos, FJ | 1 |
| Moneva-Léniz, LM | 1 |
| Gegúndez-Hernández, H | 1 |
| Prats-Máñez, A | 1 |
| Mateu-Puchades, A | 1 |
| Upputuri, B | 1 |
| Pallapati, MS | 1 |
| Tarwater, P | 1 |
| Srikantam, A | 1 |
| de Jesus, SM | 1 |
| Narang, T | 3 |
| Ashraf, R | 1 |
| Kaushik, A | 2 |
| Dogra, S | 3 |
| Chhabria, BA | 1 |
| Pannu, AK | 1 |
| Bhalla, A | 1 |
| de Carvalho, DS | 1 |
| Silva, BJA | 1 |
| Hacker, MA | 1 |
| Nery, JAC | 1 |
| Pinheiro, RO | 2 |
| Sampaio, EP | 5 |
| Daxbacher, ELR | 1 |
| Mehta, N | 1 |
| Ramachandran, R | 1 |
| Srikanth, S | 1 |
| Darlong, J | 1 |
| Govindharaj, P | 1 |
| Charles, DE | 1 |
| Menzies, A | 1 |
| Mani, S | 1 |
| Tavares Rodrigues, F | 1 |
| Pereira Cardozo, MR | 1 |
| da Costa Nery, JA | 1 |
| Vijendran, P | 1 |
| Verma, R | 2 |
| Vasudevan, B | 2 |
| Mitra, D | 2 |
| Badad, A | 1 |
| Neema, S | 1 |
| Pragasam, V | 1 |
| Moorchung, N | 1 |
| Gopal, M | 1 |
| Baek, MC | 1 |
| Jung, B | 1 |
| Kang, H | 1 |
| Lee, HS | 1 |
| Bae, JS | 1 |
| Leon, KE | 1 |
| Salinas, JL | 1 |
| McDonald, RW | 1 |
| Sheth, AN | 1 |
| Fairley, JK | 1 |
| Khodke, A | 1 |
| Shetty, VP | 1 |
| Ganesan, V | 1 |
| Mandal, J | 1 |
| Prata, RB | 1 |
| Barbosa, MG | 1 |
| Rodrigues, LS | 1 |
| Costa, Fda M | 1 |
| Dos Santos, JB | 1 |
| Pacheco, Fdos S | 1 |
| Machado, Ade M | 1 |
| Nery, JA | 4 |
| Hacker, Mde A | 1 |
| Sales, AM | 2 |
| Vetrichevvel, TP | 1 |
| Pise, GA | 1 |
| Thappa, DM | 1 |
| Feuth, M | 1 |
| Brandsma, JW | 1 |
| Faber, WR | 1 |
| Bhattarai, B | 1 |
| Feuth, T | 1 |
| Anderson, AM | 1 |
| Van Veen, NH | 2 |
| Lockwood, DN | 2 |
| van Brakel, WH | 2 |
| Ramirez, J | 2 |
| Richardus, JH | 2 |
| Kaur, I | 1 |
| De, D | 1 |
| Fabi, SG | 1 |
| Hill, C | 1 |
| Witherspoon, JN | 1 |
| Boone, SL | 1 |
| West, DP | 1 |
| Vieira, JL | 1 |
| Valente, Mdo S | 1 |
| Nau, JY | 1 |
| Ishii, N | 2 |
| Shannon, EJ | 4 |
| Sandoval, FG | 1 |
| Morales, MJ | 1 |
| Trindade, MÂ | 1 |
| Carvalho, NB | 1 |
| Belfort, EC | 1 |
| Pagliari, C | 1 |
| Gakiya, E | 1 |
| Sakai-Valente, NY | 1 |
| Benard, G | 1 |
| Shikanai-Yasuda, MA | 1 |
| Ishida, Y | 1 |
| Okano, Y | 1 |
| Ozaki, M | 1 |
| Gidoh, M | 1 |
| Kumano, K | 1 |
| Goto, M | 1 |
| Nogami, R | 1 |
| Hatano, K | 1 |
| Yamada, A | 1 |
| Yotsu, RR | 1 |
| Andres, M | 1 |
| Agullo, A | 1 |
| Negrete, R | 1 |
| Batlle, E | 1 |
| Martinez, A | 1 |
| Martiniuk, F | 1 |
| Giovinazzo, J | 1 |
| Tan, AU | 1 |
| Shahidullah, R | 1 |
| Haslett, P | 1 |
| Kaplan, G | 8 |
| Levis, WR | 2 |
| Hebe Petiti-Martin, G | 1 |
| Villar-Buill, M | 1 |
| de la Hera, I | 1 |
| Fuertes, L | 1 |
| Burgués-Calderón, M | 1 |
| Rivera-Díaz, R | 1 |
| Vanaclocha, F | 1 |
| Murthy, V | 1 |
| Horowitz, HW | 1 |
| Pham, VP | 1 |
| Wu, KL | 1 |
| Sonneveld, P | 1 |
| Teo, S | 1 |
| Resztak, KE | 1 |
| Scheffler, MA | 1 |
| Kook, KA | 2 |
| Zeldis, JB | 1 |
| Stirling, DI | 1 |
| Thomas, SD | 2 |
| Rea, TH | 2 |
| Crawford, CL | 5 |
| Okafor, MC | 1 |
| Dodd-Butera, T | 1 |
| Broderick, M | 1 |
| Perri, AJ | 1 |
| Hsu, S | 1 |
| de Carsalade, GY | 1 |
| Achirafi, A | 1 |
| Flageul, B | 1 |
| Coutsouvelis, J | 1 |
| Corallo, CE | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Murakami, H | 1 |
| Sharma, NL | 2 |
| Sharma, V | 1 |
| Shanker, V | 1 |
| Mahajan, VK | 2 |
| Sarin, S | 2 |
| Tadesse, A | 1 |
| Villahermosa, LG | 2 |
| Fajardo, TT | 1 |
| Abalos, RM | 2 |
| Balagon, MV | 2 |
| Tan, EV | 2 |
| Cellona, RV | 2 |
| Palmer, JP | 1 |
| Wittes, J | 1 |
| Walsh, GP | 2 |
| Walsh, DS | 1 |
| Haslett, PA | 1 |
| Roche, P | 1 |
| Butlin, CR | 1 |
| Macdonald, M | 1 |
| Shrestha, N | 1 |
| Manandhar, R | 1 |
| Lemaster, J | 1 |
| Hawksworth, R | 1 |
| Shah, M | 1 |
| Lubinsky, AS | 1 |
| Albert, M | 1 |
| Worley, J | 1 |
| Paumgartten, FJ | 1 |
| Chahoud, I | 1 |
| Naafs, B | 2 |
| Sharma, VC | 1 |
| Sharma, RC | 1 |
| de Matos, HJ | 1 |
| Duppre, NC | 1 |
| Kawakami, T | 1 |
| Tsutsumi, Y | 1 |
| Mizoguchi, M | 1 |
| Ishi, N | 1 |
| Soma, Y | 1 |
| Esquenazi, D | 1 |
| Moreira, AL | 3 |
| Miranda, A | 2 |
| Alvarenga, FF | 1 |
| Pereira, GM | 1 |
| Fiallo, P | 1 |
| Pesce, C | 1 |
| Lenti, E | 1 |
| Nunzi, E | 1 |
| Gardner-Medwin, JM | 1 |
| Powell, RJ | 1 |
| Jakeman, P | 1 |
| Smith, WC | 1 |
| D'Arcy, PF | 1 |
| Griffin, JP | 1 |
| Miguel, CP | 1 |
| Viana, SM | 1 |
| Malta, AM | 2 |
| Velázquez de Castro y Sagarra, A | 1 |
| López Bueno, R | 1 |
| Gómez Jiménez, G | 1 |
| Vanchieri, C | 1 |
| Calderon, P | 1 |
| Anzilotti, M | 1 |
| Phelps, R | 1 |
| Fajardo, TJ | 1 |
| Partida-Sanchez, S | 1 |
| Favila-Castillo, L | 1 |
| Pedraza-Sanchez, S | 1 |
| Gomez-Melgar, M | 1 |
| Saul, A | 1 |
| Estrada-Parra, S | 1 |
| Estrada-Garcia, I | 1 |
| Nightingale, SL | 1 |
| Couppié, P | 1 |
| Sainte-Marie, D | 1 |
| About, V | 1 |
| Heid, E | 1 |
| Pradinaud, R | 1 |
| Marriott, JB | 1 |
| Muller, G | 1 |
| Dalgleish, AG | 1 |
| Calabrese, L | 1 |
| Fleischer, AB | 1 |
| Peuckmann, V | 1 |
| Fisch, M | 1 |
| Bruera, E | 1 |
| Boisseau-Garsaud, AM | 1 |
| Vezon, G | 1 |
| Helenon, R | 1 |
| Garsaud, P | 1 |
| Saint-Cyr, I | 1 |
| Quist, D | 1 |
| Petering, H | 1 |
| Kiehl, P | 1 |
| Vogelbruch, M | 1 |
| Sticht-Groh, V | 1 |
| Kapp, A | 1 |
| Werfel, T | 1 |
| Mathé, G | 1 |
| Awofeso, N | 1 |
| Ejigu, M | 1 |
| Haile-Mariam, HS | 1 |
| Berhan, TY | 1 |
| Tasesse, G | 1 |
| Waters, MF | 1 |
| Hooper, M | 1 |
| Jew, LJ | 1 |
| Middleton, RK | 1 |
| Revuz, J | 1 |
| Randall, T | 1 |
| Salafia, A | 1 |
| Kharkar, RD | 1 |
| Bourdillon, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL[NCT03775460] | 550 participants (Anticipated) | Interventional | 2023-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for thalidomide and Leprosy, Cutaneous
| Article | Year |
|---|---|
The organization, weaknesses, and challenges of the control of thalidomide in Brazil: A review.
Topics: Abnormalities, Drug-Induced; Brazil; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; | 2020 |
Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety?
Topics: Brazil; Drug Monitoring; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy; Leprosy, Lep | 2022 |
Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Topics: Anti-Inflammatory Agents; Erythema Nodosum; Glucocorticoids; Humans; Inflammation; Leprostatic Agent | 2018 |
Novel insight into drug repositioning: Methylthiouracil as a case in point.
Topics: Animals; Anti-Inflammatory Agents; Antithyroid Agents; Arthritis, Rheumatoid; Biomarkers; Doxycyclin | 2015 |
Interventions for erythema nodosum leprosum.
Topics: Aspirin; Clofazimine; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Prednisolo | 2009 |
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous | 2009 |
Interventions for erythema nodosum leprosum. A Cochrane review.
Topics: Aspirin; Clofazimine; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Prednisolo | 2009 |
A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature.
Topics: Adrenal Cortex Hormones; Brazil; Chagas Cardiomyopathy; Erythema Nodosum; Female; Heart Diseases; Hu | 2011 |
[Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].
Topics: Erythema Nodosum; Humans; Japan; Leprostatic Agents; Leprosy, Lepromatous; Practice Guidelines as To | 2011 |
[Thalidomide: new uses for an old drug].
Topics: Angiogenesis Inhibitors; Drug Approval; Erythema Nodosum; Graft vs Host Disease; Humans; Immune Syst | 2002 |
Thalidomide in the treatment of leprosy.
Topics: Drug Therapy, Combination; Erythema Nodosum; Humans; Incidence; Leprostatic Agents; Leprosy; Leprosy | 2002 |
Thalidomide for erythema nodosum leprosum and other applications.
Topics: Animals; Cachexia; Erythema Nodosum; Graft vs Host Disease; Humans; Leprosy, Lepromatous; Multiple M | 2003 |
A review of thalidomide's history and current dermatological applications.
Topics: Dermatologic Agents; Erythema Nodosum; History, 20th Century; History, 21st Century; Humans; Leprosy | 2003 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma].
Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu | 2004 |
Treatment of leprosy: science or politics?
Topics: Attitude to Health; Erythema Nodosum; Health Knowledge, Attitudes, Practice; Health Policy; Humans; | 2006 |
Thalidomide revisited.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Animals; Behcet Syndrome; Bone Marr | 1994 |
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A | 1996 |
Thalidomide in dermatology. New indications for an old drug.
Topics: Abnormalities, Drug-Induced; Erythema Nodosum; History, 20th Century; Humans; Immunosuppressive Agen | 1997 |
Thalidomide as an emerging immunotherapeutic agent.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Anti-Inflam | 1999 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Potential novel uses of thalidomide: focus on palliative care.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Cytokines; Erythema Nodosum; Graft vs Host Disease; Huma | 2000 |
Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions.
Topics: Erythema Nodosum; Female; Humans; Immunosuppressive Agents; Leprosy, Lepromatous; Male; Prognosis; T | 2000 |
Thalidomide in erythema nodosum leprosum.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1990 |
[Current use of thalidomide].
Topics: Abnormalities, Drug-Induced; Behcet Syndrome; Dose-Response Relationship, Drug; Humans; Leprosy, Lep | 1990 |
8 trials available for thalidomide and Leprosy, Cutaneous
| Article | Year |
|---|---|
Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Erythema Nodosum; Female; Humans; Leprosta | 2008 |
Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythem | 2009 |
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr | 2003 |
A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erythema Nodosum; Humans; | 2005 |
Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy.
Topics: Adolescent; Adult; Double-Blind Method; Erythema Nodosum; Female; Humans; Leprostatic Agents; Lepros | 2007 |
Cytokine regulation of disease progression in leprosy and tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Cytokines; Erythema Nodosum; HIV-1; Humans; Immunity, Cellula | 1994 |
Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Erythema Nodosum; Humans; Interferon-gamma; Leprost | 1996 |
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Data Interpretation, Statistical; Erythema Nodosum; | 1998 |
71 other studies available for thalidomide and Leprosy, Cutaneous
| Article | Year |
|---|---|
Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Topics: Adult; Contraceptive Agents, Female; Desogestrel; Drug Implants; Drug Interactions; Erythema Nodosum | 2022 |
Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum.
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepro | 2021 |
Successful treatment of erythema nodosum leprosum with apremilast.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Panniculitis; Thalidomide | 2022 |
A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highlighting its mechanistic rationale in a resource-constrained target population.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Pannicu | 2023 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Late-onset ulnar neuritis following treatment of lepromatous leprosy infection.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Humans; Leprostatic Agents; Leprosy, Lepro | 2019 |
Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10.
Topics: Adult; Cells, Cultured; Cytokines; Erythema Nodosum; Female; Humans; Inflammation Mediators; Interle | 2020 |
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythema Nodosum; Female; Humans; Infant; Leprosta | 2020 |
Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments?
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2021 |
Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India.
Topics: Adult; Erythema Nodosum; Female; Humans; India; Leprostatic Agents; Leprosy, Lepromatous; Male; Midd | 2020 |
Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Pilot Projects; Prospective | 2021 |
Venous thrombo-embolism: thalidomide and leprosy.
Topics: Computed Tomography Angiography; Electrocardiography; Erythema Nodosum; Humans; Leprosy, Lepromatous | 2017 |
Elevated Pentraxin-3 Concentrations in Patients With Leprosy: Potential Biomarker of Erythema Nodosum Leprosum.
Topics: Adolescent; Adult; Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Child; Enzyme-Linked | 2017 |
Erythema Necroticans - A Case Report.
Topics: Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Neutrophils; Thalidomide | 2016 |
Experiences with Thalidomide for Erythema Nodosum Leprosum– a retrospective study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; | 2016 |
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release.
Topics: Antifungal Agents; Brazil; Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromato | 2018 |
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2020 |
Rare atypical presentations in Type 2 lepra reaction: a case series.
Topics: Adult; Erythema Nodosum; Female; Humans; Immune Complex Diseases; Leprostatic Agents; Leprosy, Lepro | 2014 |
Bullous erythema nodosum leprosum manifesting in the post partum period with unusual features.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromato | 2015 |
Complex Type 2 Reactions in Three Patients with Hansen's Disease from a Southern United States Clinic.
Topics: Adult; Aged; Anti-Inflammatory Agents; Asia, Southeastern; Bangladesh; Erythema Nodosum; Female; Geo | 2015 |
Type 1 reaction masquerading clinically as ENL: A Case Report.
Topics: Adult; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Thalidomide | 2015 |
Primary oral tuberculosis in a patient with lepromatous leprosy: Diagnostic dilemma.
Topics: Anti-Inflammatory Agents; Clofazimine; Coinfection; Female; Humans; Leprostatic Agents; Leprosy, Lep | 2016 |
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
Topics: Adolescent; Adult; Aged; Biopsy; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Bord | 2016 |
A case report of venous thrombosis in a leprosy patient treated with corticosteroid and thalidomide.
Topics: Adrenal Cortex Hormones; Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide; V | 2008 |
Thalidomide levels in patients with erythema nodosum leprosum.
Topics: Adult; Chromatography, Liquid; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; M | 2009 |
[Thalidomide: new therapeutic indications?].
Topics: Angiogenesis Inhibitors; Humans; Leprostatic Agents; Leprosy, Lepromatous; Telangiectasia, Hereditar | 2010 |
[Thalidomide--coverage by health insurance when used for treatment of ENL].
Topics: Adult; Aged; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Erythema Nodosum; Fe | 2010 |
In vitro thalidomide does not interfere with the activation of complement by M. leprae.
Topics: Animals; Complement Activation; Complement System Proteins; Erythema Nodosum; Humans; Leprostatic Ag | 2011 |
Lepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in Spain.
Topics: Acute Disease; Adult; Arthritis; Biopsy; Colombia; Emigration and Immigration; Humans; Leprostatic A | 2012 |
Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity.
Topics: Adolescent; Adult; Biopsy; Cytokines; Erythema Nodosum; Gene Expression Regulation; Humans; Interleu | 2012 |
Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction.
Topics: Adult; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Thalidomide; Venous Thrombosis | 2013 |
Giant PPD reaction with positive QuantiFERON-TB Gold in a patient with lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Interferon-gamma Release Tests; Latent Tuberculosis; Leprosy, Lepro | 2012 |
Elevated platelet counts and thrombocytosis in erythema nodosum leprosum.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Mexico; Mid | 2002 |
The schizophrenic career of a "monster drug".
Topics: Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Nervous System | 2003 |
Thalidomide makes a comeback.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Ectromelia; Erythema Nodosum; Female; Humans; | 2003 |
Licensing thalidomide in Australia.
Topics: Australia; Drug and Narcotic Control; Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 2004 |
Thalidomide-induced bradycardia and its management.
Topics: Aged; Bradycardia; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiograp | 2004 |
Does thalidomide have a role in leprosy?
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2004 |
Deep vein thrombosis: a rare complication of thalidomide therapy in recurrent erythema nodosum leprosum.
Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Erythema Nodosum; Female; Glucoco | 2004 |
Concerns regarding in vitro and in vivo uses of thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2005 |
Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Erythema Nodos | 2005 |
Thalidomide embryopathy cases in Brazil after 1965.
Topics: Adult; Brazil; Drug Utilization Review; Erythema Nodosum; Female; Fetal Diseases; Humans; Leprosy, L | 2006 |
No role for thalidomide in the treatment of leprosy.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Thalidomide | 2006 |
Erythema nodosum leprosum and HIV infection: A therapeutic experience.
Topics: Adult; Anti-HIV Agents; Colchicine; Erythema Nodosum; HIV Infections; Humans; Ibuprofen; Leprostatic | 2005 |
Clinicopathologic challenge.
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; Extremities; Facial Dermatoses; Female; Humans; Le | 2007 |
Clinical, immunological and histological aspects of an uncommon type II reaction in patients with lepromatous leprosy.
Topics: Aged; Antiviral Agents; Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Lepromatous; Male; Midd | 2008 |
Short report: erythema nodosum leprosum lymphadenitis.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Lymph Nodes; Lymphadenitis; Male; Middle Aged; Thali | 1995 |
Thalidomide--the way forward.
Topics: Abnormalities, Drug-Induced; Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1994 |
Thalidomide in leprosy reaction.
Topics: Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Pregnancy; Thalidomide | 1994 |
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Male; Middle Aged; Thalidomide; Tumor | 1993 |
[Suspected leprosy].
Topics: Adult; Aged; Aged, 80 and over; Dapsone; Diagnosis, Differential; Female; Humans; Leprostatic Agents | 1997 |
Preparing for thalidomide's comeback.
Topics: Drug Approval; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Tha | 1997 |
Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL.
Topics: Adolescent; Adult; Cytokines; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Male; Pentoxif | 1998 |
From the Food and Drug Administration.
Topics: Drug Approval; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Policy Making; Th | 1998 |
[Bullous erythema nodosum leprosum. A case report in French Guiana].
Topics: Adult; Diagnosis, Differential; Erythema Nodosum; French Guiana; Humans; Leprostatic Agents; Leprosy | 1998 |
Thalidomide.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Inf | 1998 |
Thalidomide: new preparation. For well-defined indications.
Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans; | 1998 |
High prevalence of vitiligo in lepromatous leprosy.
Topics: Adult; Aged; Aged, 80 and over; Clofazimine; Dapsone; Female; Humans; Leprostatic Agents; Leprosy, L | 2000 |
[Chemotherapy-induced erythema nodosum leprosum: successful treatment with thalidomide].
Topics: Adult; Dapsone; Dermatologic Agents; Drug Therapy, Combination; Erythema Nodosum; Follow-Up Studies; | 2001 |
Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system.
Topics: Acquired Immunodeficiency Syndrome; Erythema Nodosum; Graft vs Host Reaction; Humans; Immunosuppress | 2002 |
24th Kellersberger Memorial lecture, 1999 thalidomide: will the past overshadow a promising future?
Topics: Erythema Nodosum; Humans; Immunity, Cellular; Leprostatic Agents; Leprosy, Lepromatous; T-Lymphocyte | 1999 |
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy.
Topics: Anemia; Dapsone; Erythema Nodosum; Hemoglobins; Humans; Leprostatic Agents; Leprosy, Lepromatous; Pr | 2001 |
Thalidomide peripheral neuropathy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Nigeria; Peripheral Nervous System Diseases; T | 1992 |
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
Topics: Adult; CD4-CD8 Ratio; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide | 1992 |
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.
Topics: Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Borderline; Leprosy, Lepromatous; Monocytes; Re | 1992 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Peripheral Nervous System Diseases; Thalidomide | 1991 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1991 |
Use of thalidomide in leprosy.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Thalidomide | 1991 |
Investigational new drug (US) 'orphan' trials now use thalidomide from two sources.
Topics: Drug Industry; Erythema Nodosum; Graft vs Host Disease; Leprosy, Lepromatous; Orphan Drug Production | 1990 |
Thalidomide and exfoliative dermatitis.
Topics: Drug Eruptions; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Middle Aged; Thalidomide | 1988 |
Thalidomide in erythema nodosum leprosum (ENL)
Topics: Adult; Erythema Nodosum; Humans; Leprosy, Lepromatous; Male; Thalidomide | 1988 |